Killing Part D Rebates For Duals Could Cost Pharma Another $12 Billion
This article was originally published in The Pink Sheet Daily
Executive Summary
As health care reform approaches a House-Senate conference, there is speculation that pharma will commit more money in order to keep the door closed on broader rebates.
You may also be interested in...
As Health Reform Takes Final Shape, Pharma Provisions Still In Play
Even as news that a breakthrough on one of the major issues separating the House and Senate health care reform bills - taxing high-cost health care plans -emerged near the end of the week of Jan. 11, issues of keen interest for biopharma stakeholders remained unsettled
As Health Reform Takes Final Shape, Pharma Provisions Still In Play
Even as news that a breakthrough on one of the major issues separating the House and Senate health care reform bills - taxing high-cost health care plans -emerged near the end of the week of Jan. 11, issues of keen interest for biopharma stakeholders remained unsettled
Rx Price Hikes In Advance Of Health Bill Will Get OIG Probe
Sen. Bill Nelson continues campaign to extract more concessions from pharmaceutical industry as part of health care reform legislation.